What is the recommended management for coronary artery disease?

Management of Coronary Artery Disease

All patients with CAD require comprehensive medical therapy combining lifestyle interventions, antiplatelet agents, statins, and symptom-directed antianginal medications, with revascularization reserved for specific anatomic patterns or refractory symptoms. 1

Lifestyle Management (Foundation of All Treatment)

The following interventions are mandatory for all CAD patients 1:

• Exercise-based cardiac rehabilitation - reduces mortality and improves quality of life
• Cognitive behavioral interventions - to achieve sustainable lifestyle changes
• Annual influenza vaccination - especially in elderly patients
• Multidisciplinary team involvement - cardiologists, nurses, dieticians, physiotherapists, psychologists, pharmacists
• Psychological interventions - for depression symptoms which are common and worsen outcomes

Medical Therapy Algorithm

1. Event Prevention (All Patients)

Antiplatelet Therapy:

• Aspirin 75-100 mg daily for patients with previous MI or revascularization 1
• Clopidogrel 75 mg daily as alternative if aspirin intolerance 1

Lipid Management (Aggressive Approach):

• Statins are mandatory in ALL patients with CAD 1
• If LDL goals not met on maximum tolerated statin: add ezetimibe 1
• If still not at goal on statin + ezetimibe: add PCSK9 inhibitor 1

ACE Inhibitors/ARBs:

• Recommended in presence of heart failure, hypertension, or diabetes 1
• Consider in all patients with atherosclerosis 1

Gastrointestinal Protection:

• Proton pump inhibitor recommended for patients on aspirin monotherapy, DAPT, or anticoagulation who are at high GI bleeding risk 1

2. Symptom Relief (Symptomatic Patients)

First-Line Antianginal Therapy:

• Short-acting nitrates for immediate relief of effort angina 1
• Beta-blockers and/or calcium channel blockers (CCBs) for heart rate and symptom control 1

Critical Contraindication:

• Never use nitrates in hypertrophic obstructive cardiomyopathy or with phosphodiesterase inhibitors 1

Follow-up:

• Review response at 2-4 weeks after drug initiation 1
• Patient education about disease, risk factors, and treatment strategy is mandatory 1

3. Special Populations

Diabetes:

• SGLT2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) are recommended 1
• GLP-1 receptor agonists (liraglutide or semaglutide) are recommended 1
• ACE inhibitors recommended for event prevention 1

Atrial Fibrillation:

• NOAC preferred over warfarin when initiating anticoagulation 1
• Long-term anticoagulation if CHA₂DS₂-VASc score >2 (males) or >3 (females) 1
• Do NOT use ticagrelor or prasugrel as part of triple therapy with aspirin and anticoagulation 1

Post-PCI:

• Aspirin 75-100 mg daily indefinitely 1
• Clopidogrel 75 mg daily (after appropriate loading) for 6 months after stenting, regardless of stent type 1
• Shorter duration (1-3 months) if life-threatening bleeding risk 1

Heart Failure with CAD:

• Beta-blockers - essential for angina relief AND mortality reduction 1
• ACE inhibitors - reduce morbidity and mortality 1
• Mineralocorticoid receptor antagonist if symptomatic despite ACE inhibitor and beta-blocker 1
• Diuretics for congestion 1

Revascularization Indications

Prognostic Benefit (Improves Survival)

Mandatory revascularization for: 2

• Left main stenosis (functionally significant) with LVEF >35%
• Three-vessel disease (functionally significant) with LVEF >35%
• Single or two-vessel disease involving proximal LAD (functionally significant) with LVEF >35%

LVEF ≤35%:

• CABG recommended over medical therapy alone for multivessel disease 2
• Heart Team evaluation required to assess coronary anatomy, correlation with LV dysfunction, comorbidities, life expectancy 2

Symptomatic Benefit

Revascularization recommended when:

• Persistent angina despite guideline-directed medical therapy 2
• Functionally significant obstructive CAD documented 2

Physiologic Guidance is Mandatory

• FFR or iwFR required to complement invasive angiography when assessing high-risk patients or those with inadequate symptom response 1
• Invasive angiography NOT recommended solely for risk stratification 1

Common Pitfalls to Avoid

1. Do not skip statins - they are Class I recommendation for ALL CAD patients, not just those with elevated cholesterol 1

2. Do not use nitrates with phosphodiesterase inhibitors - can cause life-threatening hypotension 1

3. Do not continue dual antiplatelet therapy indefinitely - 6 months post-PCI is standard unless specific high-risk features 1

4. Do not forget PPI - high GI bleeding risk is common with antiplatelet/anticoagulation therapy 1

5. Do not revascularize based on anatomy alone - functional significance (FFR/iwFR) must guide decisions 1, 2

6. Do not use ticagrelor or prasugrel with triple therapy - excessive bleeding risk when combined with aspirin and anticoagulation 1